Nanomedicine therapeutic approaches to overcome cancer drug resistance

By J. Markman, A. Rekechenetskiy, E. Holler, J. Ljubimova. Advanced Drug Delivery Reviews, 2013

675 citations recorded by the source corpus.

Nanomedicine is an emerging form of therapy that focuses on alternative drug delivery and improvement of the treatment efficacy while reducing detrimental side effects to normal tissues. Cancer drug resistance is a complicated process that involves multiple mechanisms. Here we discuss the major forms of drug resistance and the new possibilities that nanomedicines offer to overcome these treatment obstacles. Novel nanomedicines that have a high ability for flexible, fast drug design and production based on tumor genetic profiles can be created making drug selection for personal patient treatment much more intensive and effective. This review aims to demonstrate the advantage of the young medical science field of nanomedicine for overcoming cancer drug resistance. With the advanced design and alternative mechanisms of drug delivery known for different nanodrugs including liposomes, polymer conjugates, micelles, dendrimers, carbon-based, and metallic nanoparticles, overcoming various forms of multi-drug resistance looks promising and opens new horizons for cancer treatment.

Subfields: Biomaterials, Biomedical Engineering, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/45ee9c859bb1f5d84491499a8da3d69d2e4c8976

Citations in the corpus

• Development of Exosome-encapsulated Paclitaxel to Overcome MDR in Cancer cells (2015, neutral): “To date, there has been limited success in overcoming drug resistance in cancers through the use of novel small molecule chemotherapeutics (5, 6), or nanoformulations of existing chemotherapeutics (7-9).”